CYP3A4 and cancer: Furthermore, a meta-analysis of oral clearance values in healthy volunteers versus cancer patients showed similar elimination across several CYP3A4 substrates, including imatinib, everolimus, ibrutinib, midazolam, dastanib and nilotinib [25,26].